Amundi Index Solutions - Amundi Index MSCI Europe A3E-DRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 2.3 | 17.7 | -4.1 | 13.4 | 9.3 | |
+/-Cat | -2.0 | 2.3 | 4.2 | 1.8 | 1.9 | |
+/-B’mrk | -0.2 | 0.0 | 0.5 | 0.2 | 0.0 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 25/09/2024 | EUR 161.42 | |
Day Change | 0.20% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | LU1327398977 | |
Fund Size (Mil) 25/09/2024 | EUR 4374.69 | |
Share Class Size (Mil) 25/09/2024 | EUR 0.06 | |
Max Initial Charge | 4.50% | |
Ongoing Charge 22/06/2024 | 0.13% |
Investment Objective: Amundi Index Solutions - Amundi Index MSCI Europe A3E-D |
To track the performance of MSCI Europe Index (the "Index"), and to minimize the tracking error between the net asset value of the sub-fund and the performance of the Index. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Isabelle Lafargue 07/09/2015 | ||
Inception Date 12/04/2016 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Amundi Index Solutions - Amundi Index MSCI Europe A3E-D | 24/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 3.54 |
ASML Holding NV | Technology | 2.85 |
Nestle SA | Consumer Defensive | 2.29 |
SAP SE | Technology | 2.12 |
AstraZeneca PLC | Healthcare | 2.11 |
Increase Decrease New since last portfolio | ||
Amundi Index Solutions - Amundi Index MSCI Europe A3E-D |